Amanta Healthcare Limited conducted its first earnings conference call on February 11, 2026, following the release of Q3 and nine-month FY26 financial results. The pharmaceutical company, led by Chairman and Managing Director Bhavesh Patel, outlined ambitious expansion plans and provided detailed insights into its growth strategy during the investor interaction.

Q3FY26 and Nine-Month Performance Overview

The company maintained its growth trajectory with consistent performance across key financial metrics. Management emphasized the transition from an investment-led phase to a structurally profitable growth phase, supported by operational discipline and strategic initiatives.

Major Capacity Expansion Plans Detailed

During the conference call, management provided comprehensive details about ongoing expansion initiatives. The company is implementing a significant capacity enhancement program across both Large Volume Parenteral (LVP) and Small Volume Parenteral (SVP) segments.

Bhavesh Patel confirmed that the SteriPort expansion is expected to commence commercial production by April 2026, with full-scale operations anticipated by the end of the financial year. The incremental revenue from SteriPort alone is projected at ₹120 crore, while the combined expansion could generate ₹150 crore in additional revenue.

SteriPort Technology Leadership and Market Position

Management extensively discussed the company's competitive advantages in the two-port IV fluid container system. Patel highlighted that Amanta was the first company in India to introduce SteriPort technology, which utilizes advanced Injection Stretch Blow Moulding (ISBM) technology with random copolymer polypropylene material.

The company's SteriPort containers can withstand sterilization at 125°C, significantly higher than competitors' polyethylene-based products that cannot exceed 109°C. This technical superiority provides absolute sterilization and reduces contamination risks in critical care applications.

Financial Projections and Debt Management Strategy

CFO Paras Mehta outlined the company's financial roadmap, projecting revenues of approximately ₹400 crore for FY27 from SteriPort expansion alone. The management detailed their debt reduction strategy, targeting annual repayments of ₹35-40 crore through improved cash flows.

Solar Power Initiative and Cost Optimization

The company announced a 10.8 megawatt captive solar power plant investment, expected to be operational by May 2026. This initiative is projected to generate annual cost savings of ₹9 crore at the EBITDA level, enhancing operational efficiency and sustainability.

Management emphasized that despite taking additional debt for the solar project, the net debt position will improve due to accelerated repayments from enhanced cash flows and operational savings.

Amanta Healthcare Limited has announced changes in its senior management personnel structure, with the Board of Directors approving key appointments and removals effective February 10, 2026. The pharmaceutical company has formally communicated these changes to stock exchanges in compliance with regulatory requirements.

Board Approval and Regulatory Compliance

The Board of Directors of Amanta Healthcare Limited, acting on recommendations from the Nomination and Remuneration Committee, approved the senior management changes on February 10, 2026. The company has notified both BSE Limited (Scrip Code: 544502) and National Stock Exchange of India Limited (Trading Symbol: AMANTA) about these personnel changes pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Senior Management Personnel Changes

The company announced two significant changes to its senior management team:

Profile of New Senior Management Personnel

Shri Urmil Oza brings substantial experience and expertise to his role as Senior Management Personnel. His professional background includes:

Key Responsibilities and Expertise

Urmil Oza's extensive experience encompasses multiple critical areas within the organization:

• Production Engineering: Leading production engineering operations and utility equipment management
• Project Management: Overseeing project activities and technical procurement processes
• Vendor Relations: Managing all plant and utility side vendor communications
• Equipment Management: Handling utility and plant equipment maintenance and operational management on a routine basis
• Regulatory Compliance: Managing all government-related documentation and compliance requirements

Corporate Governance

The announcement was signed by Nikhita Dinodia, Company Secretary and Compliance Officer (Membership No. 53362), ensuring proper corporate governance protocols. The company has requested both stock exchanges to take note of these changes in their records, maintaining transparency with stakeholders and regulatory bodies.